In an interview with Christine Moutier, MD, psychiatrist and chief medical officer of the American Foundation for Suicide Prevention, she speaks about how the current COVID-19 pandemic presents opportunities to improve suicide prevention efforts on multiple levels.
Anna Lembke, MD, discusses how patients who use drugs are affected by the convergence of 2 public health emergencies – increasing overdose rates, and the COVID-19 pandemic – and addresses controversial solutions proposed by other investigators.
Monisha Sharma, PhD, and Charlene Dewey, MD, provide insight into the current landscape that leads to physician burnout and the next steps to combat it.
An overview of the risk for infections during targeted and biological therapies in rheumatoid arthritis and psoriatic arthritis.
While the rate of certain HIV-linked non-Hodgkin lymphomas has declined since the introduction of ART, the incidence of Burkitt lymphoma has remained steady.
Numerous reports have indicated gastrointestinal, cardiovascular, and neurologic manifestations, in addition to the noted respiratory effects, in patients with COVID-19, and up to 50% of patients with COVID-19 may experience hepatic manifestations.
Due to innate and adaptive immune alterations and the risk for nosocomial infection from exposure to potentially infected blood-borne sources, patients with end-stage renal disease (ESRD) have an elevated risk of contracting viral infections.
The estimated US prevalence of HBV is roughly 2% in the general population and 0.7% to 0.9% among pregnant women.
The PA-I38 mutations were noted frequently in influenza A/H3N2 viruses compared with A/H1N1pdm or influenza B viruses.
In the United States, approximately 3.5 million people are infected with the hepatitis C virus, which contributes to psychological and cognitive disorders for about half of all patients.
